Apnimed, Inc. Common Stock(APMD)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$16.92
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for APMD

11/13/2026: APMD (1-star) is currently NOT-A-BUY. Pass it for now.

Apnimed is a clinical-stage biotechnology company focused on developing novel oral pharmacotherapies for obstructive sleep apnea. The company's primary strength lies in its lead candidate, AD109, which targets the neuromuscular root cause of sleep-disordered breathing for patients intolerant to traditional mechanical devices. Its main growth opportunity centers on capturing a major share of an extensive global patient population seeking a convenient alternative to CPAP machines. Key risks include clinical execution hurdles, regulatory review outcomes, and aggressive competition from alternative metabolic therapies and medical devices. The stock is best suited for growth-oriented investors willing to accept high volatility in exchange for potential clinical milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitApnimed offers high-growth exposure centered on a novel therapeutic category in sleep medicine.
Momentum investorStrong fit while signal remains positiveThe stock can exhibit sharp price movements around clinical catalysts and regulatory milestones.
Value investorWeak fitThe company lacks current earnings and traditional positive cash flow metrics.
Dividend investorWeak fitApnimed does not pay dividends and retains all capital for clinical advancement.
Low-risk investorWeak fitClinical-stage biotechnology equities carry high binary regulatory and clinical trial risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks frequently experience dramatic price swings based on news flow.
Valuation riskMedium / highValuations depend heavily on forward-looking commercial assumptions rather than current revenues.
Competition risk (alternative metabolic and device therapies)Medium / highAlternative treatments from larger pharmaceutical and medical device competitors could capture market share.
Business qualityMediumThe core science is backed by robust academic research, but commercial viability remains unproven.
Dividend incomeLow / noneNo dividend payments are distributed to shareholders.
Execution riskHighSuccessful commercialization depends entirely on regulatory approval and market execution.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 704.39M USD
Price to earnings Ratio 2.34
1Y Target Price 50.33
Price to earnings Ratio 2.34
1Y Target Price 50.33
Volume (30-day avg) 397.3K shares
Beta -
52 Weeks Range 13.88 - 35.29
Updated Date 11/15/2026
52 Weeks Range 13.88 - 35.29
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 7.22

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Insufficient Data
PRICE PATH

Insufficient Data

The stock demonstrates a Insufficient Data price path pattern.

Insufficient Data
PRICE STABILITY

Insufficient Data

The stock price exhibits a Insufficient Data stability pattern.

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
APMD receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
APMD has solid overall fundamentals (4 stars), with soft financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+99.2%) and strong revenue growth (+380.1%) are partially offset by weak cash generation (FCF margin -202.3%), weak profitability (net margin -2.4%).

Financial Health Rating

★★★★★
APMD's financial health is soft, with the relatively strongest area being moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 222.5% of revenue). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is APMD's strongest growth driver at +380.1% FY2025 versus FY2024 (strong, 5 stars). Earnings growth (+99.2%, strong) and free-cash-flow growth (+29.4%, solid) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 57.6% and approximately 52.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 43.14% supports management-shareholder alignment.

Top 5 Institutional Investors

Aberdeen Group PLC 2.27%
Sectoral Asset Management Inc 2.26%
Rhumbline Advisers 0.03%

Unit Economics (Per $1K Revenue)

★★★★★
APMD generates approximately $826 of gross profit, $-1,399 of operating income, and $-2,023 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and moderate capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
APMD has a high-quality, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Quality TiltLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic Product Sales (Future)Future commercial sales of oral drug candidates like AD109 for obstructive sleep apnea.The company is pre-revenue and intends to generate future sales primarily through prescription pharmaceutical commercialization.

Valuation

Trailing PE 2.34
Forward PE -
Enterprise Value 611.94M
Price to Sales(TTM) 6.12
Enterprise Value 611.94M
Price to Sales(TTM) 6.12
Enterprise Value to Revenue 5.32
Enterprise Value to EBITDA 17.19
Shares Outstanding 41.63M
Shares Floating 21.69M
Shares Outstanding 41.63M
Shares Floating 21.69M
Percent Insiders 43.14
Percent Institutions 57.63

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.